The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand α-Galactosylceramide
Open accessAbstract
α-Galactosylceramide (α-GalCer) is a glycolipid that stimulates natural killer T cells to produce both T helper (Th) 1 and Th2 cytokines. This property enables α-GalCer to ameliorate a wide variety of infectious, neoplastic, and autoimmune diseases; however, its effectiveness against any one disease is limited by the opposing activities of the induced Th1 and Th2 cytokines. Here, we report that a synthetic C-glycoside analogue of α-GalCer, α-C-galactosylceramide (α-C-GalCer), acts as natural killer T cell ligand in vivo, and stimulates an enhanced Th1-type response in mice. In two disease models requiring Th1-type responses for control, namely malaria and melanoma metastases, α-C-GalCer exhibited a 1,000-fold more potent antimalaria activity and a 100-fold more potent antimetastatic activity than α-GalCer. Moreover, α-C-GalCer consistently stimulated prolonged production of the Th1 cytokines interferon-γ and interleukin (IL)-12, and decreased production of the Th2 cytokine IL-4 compared with α-GalCer. Finally, α-C-GalCer's enhanced therapeutic activity required the presence of IL-12, which was needed to stimulate natural killer cells for optimal interferon-γ production, but did not affect IL-4. Overall, our results suggest that α-C-GalCer may one day be an excellent therapeutic option for diseases resolved by Th1-type responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CD1d-Restricted and TCR-Mediated Activation of V α 14 NKT Cells by Glycosylceramides
Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., Nakagawa, R., Sato, H., Kondo, E., et al. (1997) · Science · doi:10.1126/science.278.5343.1626 · Cited by 2,400
MOUSE CD1-SPECIFIC NK1 T CELLS: Development, Specificity, and Function
Bendelac, A., Rivera, M. N., Park, S.-H., & Roark, J. H. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.535 · Cited by 1,326
Requirement for V α 14 NKT Cells in IL-12-Mediated Rejection of Tumors
Cui, J., Shin, T., Kawano, T., Sato, H., Kondo, E., Toura, I., Kaneko, Y., Koseki, H., Kanno, M., & Taniguchi, M. (1997) · Science · doi:10.1126/science.278.5343.1623 · Cited by 1,237
Chan, S. H., Perussia, B., Gupta, J. W., Kobayashi, M., Pospísil, M., Young, H. A., Wolf, S. F., Young, D., Clark, S. C., & Trinchieri, G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.4.869 · Cited by 961
Tracking the Response of Natural Killer T Cells to a Glycolipid Antigen Using Cd1d Tetramers
Matsuda, J. L., Naidenko, O. V., Gapin, L., Nakayama, T., Taniguchi, M., Wang, C.-R., Koezuka, Y., & Kronenberg, M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.5.741 · Cited by 887
Miyamoto, K., Miyake, S., & Yamamura, T. (2001) · Nature · doi:10.1038/35097097 · Cited by 874
NKT cells: facts, functions and fallacies
Godfrey, D. I., Hammond, K. J. L., Poulton, L. D., Smyth, M. J., & Baxter, A. G. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01735-7 · Cited by 858
Carnaud, C., Lee, D., Donnars, O., Park, S.-H., Beavis, A., Koezuka, Y., & Bendelac, A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.9.4647 · Cited by 854
Sloan-Lancaster, J., & Allen, P. M. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.1 · Cited by 676
Brossay, L., Chioda, M., Burdin, N., Koezuka, Y., Casorati, G., Dellabona, P., & Kronenberg, M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.8.1521 · Cited by 642
Cited by
Regulation of Interferon‐γ During Innate and Adaptive Immune Responses
(2007) · Advances in Immunology · doi:10.1016/s0065-2776(07)96002-2 · Cited by 1,655
TOWARD AN UNDERSTANDING OF NKT CELL BIOLOGY: Progress and Paradoxes
Kronenberg, M. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115742 · Cited by 1,029
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
Going both ways: Immune regulation via CD1d-dependent NKT cells
Godfrey, D. I., & Kronenberg, M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200423594 · Cited by 877
Targeting natural killer cells and natural killer T cells in cancer
Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., & Brossay, L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3174 · Cited by 850
Dendritic Cells: Translating Innate to Adaptive Immunity
Steinman, R. M., & Hemmi, H. (2006) · Current Topics in Microbiology and Immunology · doi:10.1007/3-540-32636-7_2 · Cited by 844
Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions
Brennan, P. J., Brigl, M., & Brenner, M. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3369 · Cited by 835
The burgeoning family of unconventional T cells
Godfrey, D. I., Uldrich, A. P., McCluskey, J., Rossjohn, J., & Moody, D. B. (2015) · Nature Immunology · doi:10.1038/ni.3298 · Cited by 805
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531
Recognition of CD1d-restricted antigens by natural killer T cells
Rossjohn, J., Pellicci, D. G., Patel, O., Gapin, L., & Godfrey, D. I. (2012) · Nature Reviews Immunology · doi:10.1038/nri3328 · Cited by 460
CD1d-restricted iNKT cells, the ‘Swiss-Army knife’ of the immune system
Matsuda, J. L., Mallevaey, T., Scott-Browne, J., & Gapin, L. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.03.018 · Cited by 407
The crystal structure of human CD1d with and without α-galactosylceramide
Koch, M., Stronge, V. S., Shepherd, D., Gadola, S. D., Mathew, B., Ritter, G., Fersht, A. R., Besra, G. S., Schmidt, R. R., Jones, E. Y., et al. (2005) · Nature Immunology · doi:10.1038/ni1225 · Cited by 395
Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments
Xu, J., Ding, L., Mei, J., Hu, Y., Kong, X., Dai, S., Bu, T., Xiao, Q., & Ding, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02325-5 · Cited by 389
Harnessing invariant NKT cells in vaccination strategies
Cerundolo, V., Silk, J. D., Masri, S. H., & Salio, M. (2009) · Nature Reviews Immunology · doi:10.1038/nri2451 · Cited by 358
Modulation of CD1d-restricted NKT cell responses by using N- acyl variants of α-galactosylceramides
Yu, K. O. A., Im, J. S., Molano, A., Dutronc, Y., Illarionov, P. A., Forestier, C., Fujiwara, N., Arias, I., Miyake, S., Yamamura, T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407488102 · Cited by 337
Chapter 8 The Role of NKT Cells in Tumor Immunity
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)00408-9 · Cited by 316
Unconventional T Cell Targets for Cancer Immunotherapy
Godfrey, D. I., Le Nours, J., Andrews, D. M., Uldrich, A. P., & Rossjohn, J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.009 · Cited by 314
α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles
Kaer, L. V. (2005) · Nature Reviews Immunology · doi:10.1038/nri1531 · Cited by 299
Biology of CD1- and MR1-Restricted T Cells
Salio, M., Silk, J. D., Yvonne Jones, E., & Cerundolo, V. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120243 · Cited by 299
Metadata
- Authors
- Schmieg, J., Yang, G., Franck, R. W., & Tsuji, M.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2003-12-01
- Volume
- 198
- Issue
- 11
- Pages
- 1631-1641
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2150888484
- Cited by
- 385
- References
- 28
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.